An agreement that could significantly help poor countries access treatment for him coronavirus announcement h Pfizer. The pharmaceutical industry will allow the production of its generics pill against Covid19 in cheap editions in 95 countries.
This is an important decision by Pfizer, despite the fact that it excludes from the list of countries several that have been severely affected by the coronavirus.
According to the New York Times, Pfizer is following suit Merck and announced a licensing agreement with the UN-backed Medicines Patent Pool to extend access to its Covid-19 antiviral pill throughout the developing world. “The fact that we now have two licenses to manufacture the two drugs is a big change and is in stark contrast to the restrictive licensing so far for vaccinesSaid James Love, head of Knowledge Ecology International, a non-profit organization that researches access to medical products.
“We must work to ensure that all people – regardless of where they live or their circumstances – have access to these discoveries and we are pleased to work with the MPP to promote our commitment to equality,” he said. Albert Burla, CEO of Pfizer.
Coronavirus – Pfizer: Which countries are excluded from the agreement
Like the Merck deal, Pfizer’s excludes some of the poorest countries that have been severely affected by the coronavirus.
For example, the Brazil, the Cuba, the Iraq, the Libya and the Jamaica, coronavirus pills should be procured directly from Pfizer, probably at higher prices compared to those charged by generic manufacturers, and for these countries, there is a risk of supply disruptions.
THE China and the Russia Countries hosting a total of 1.5 billion people – are excluded from both agreements, as is Brazil.
Merck and Pfizer pills: Which “works” best and what side effects they cause
Two new “weapons” in the fight against the coronavirus are expected to be the antiviral pills of the American pharmaceutical companies Merck and Pfizer, when they become widely available. Meanwhile, the extent of their use in different groups of patients is under investigation. Initially, the pills showed great promise in adults diagnosed with Covid-19 infection, while examining whether they can prevent infection in healthy people exposed to the coronavirus.
But why are these two pills important and how do they “work”? Reuters answers questions related to what is already known.
Which pill “works” best?
Clinical trial data from both companies show that the Pfizer pill is more effective, but the company has not yet released the full data. According to Pfizer, the pill reduces by 89% the risk of hospitalization or death of high-risk patients with Covid-19, if administered within three days of the onset of symptoms, and by 85% if administered within five days .
THE Merck had earlier (October 1) announced that its own pill reduces the risk of hospitalization or death by 50% in patients at risk of severe disease if the drug is administered within the first five days after the onset of symptoms, while it did not evaluate the effectiveness of the pill given earlier, within the first three days.
Her pill Pfizer has the brand name Paxlovid, while the Merck Lavgevrio, at least in Britain where it was approved for release.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
